This site is intended for healthcare professionals
News

Ferriprox approved in Canada for treatment of iron overload in patients with sickle cell disease.

Read time: 1 mins
Last updated:21st Oct 2021
Published:21st Oct 2021
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.

Ferriprox was previously approved in Canada for the treatment of iron overload in patients with thalassemia major when current chelation therapy is inadequate.

Thalassemia major and SCD are two disorders that affect red blood cells. Both conditions cause problems with hemoglobin, depriving many parts of the body of oxygen. People living with these conditions often require chronic blood transfusions that can put them at risk of developing very high levels of iron in their blood and vital organs. Ferriprox is a synthetic, orally active iron-chelating agent shown to be effective in reducing iron concentration by penetrating cell membranes and removing toxic iron from organ tissues and extracellular fluids.

Condition: Iron Overload
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.